An interventional study of Serious Illness Care Program for Heart Failure (SICP-HF) in Heart Failure, sponsored by Abigail Latimer. Recruiting at 1 site in United States. Open to participants aged 18 Years to 105 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Abigail Latimer · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,159 studies in Heart Failure with a site in United States — 347 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.
Among the 2,159 studies in Heart Failure with a site in United States, this one is the 458th largest by planned enrollment of the 1,602 interventional ones that give a count, is one of 95 that started in 2026, is one of 887 with no phase, reaches primary completion later than 343 of the 438 other live ones, and was the 2,142nd registered.
6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →347 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80
AnaCardio AB · Sites in United States, Bulgaria, Canada and 5 more countries
Ages 18–85
Weill Medical College of Cornell University · Sites in United States
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 105 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,159 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 174 · Phase 2 313 · Phase 3 177 · Phase 4 139
First in 1983; this study’s year is marked. 95 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 76 across 4,052 interventional studies indexed under Heart Failure.
Median enrollment 66 across the 1,602 interventional studies, 150 across the 552 observational. Of the 1,510 that completed or were terminated, 629 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
747 of 2,159 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Abigail Latimer as lead sponsor.
Abigail Latimer has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
138 of the studies in Heart Failure with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02901184Phase 3Uppsala UniversitySpironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction | 2026-12 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
Add all 138 to your calendar (.ics) → With an account.
Among the 2,159 studies in Heart Failure with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Living with heart failure for adults over age 50 is hard. Older adults have to take many medicines to address heart failure and other health problems. That group of individuals must decide which medications to take and which devices to use to support heart health. Doctors, nurses, and social workers help patients understand these options but do not always know what is most important to them. Talking with patients about what the patients are hoping for, what the patients are worried about, and how much the patients understand about the illness is called a serious illness conversation, and it is hard to do. Doctors, nurses, and social workers are very busy and worry about upsetting patients by bringing up hard topics.
The Serious Illness Care Program helps doctors, nurses, and social workers have these conversations by giving the staff a script to follow on what to say. The program also includes ways to make sure staff remember to have the conversation, a brief training, and how to document what is said during the conversation. But, nobody has studied the Serious Illness Care Program in a heart failure clinic, so it has not been customized to meet the needs of heart failure teams or older adults with heart failure.
Many programs that are supposed to help patients fail in the real world. One reason is that patients do not include the needs of those who will receive and deliver it. Before this project, the team interviewed heart failure doctors, nurses, social workers, and other staff at a heart failure clinic. As well as interviewing older adults and care partners. The team asked staff how the Serious Illness Care Program can be changed to fit the needs and work in the clinic. The program includes a conversation guide that helps the team know what to say, so the study team asked patients and care partners what the thoughts on the language used and the topics covered. Then, the team practiced putting the program in place at the clinic and trained clinicians on using the Serious Illness Care Program with older adults and family members.
Now the team wants to see if the heart failure team likes it and if it is doable. The team will also ask patients and care partners about the conversation and about feelings of anxiety before, during, and after the conversation. Lastly, the team will ask the individuals before and after the conversation about patients' knowledge of heart failure and how prepared the care partner feels to care for the individual. The team also want to explore how the program helps clinicians understand patients' symptoms, quality of life, and illness knowledge.
Ultimately, this project establishes a structured framework to facilitate goals-of-care discussions between heart failure teams, patients, and families. These conversations empower patients to make immediate and future medical decisions aligned with personal values and lifestyle preferences. This values-based decision-making process optimizes care delivery and supports patients in achieving optimal health outcomes.
During this trial, the team aims to enroll three separate groups of participants: patients, care partners, and clinicians. Care partners are not required to participate with patients, but may choose to. At participating sites, trained clinician participants will identify patients through standard workflows, and research assistants will also screen clinic schedules for potentially eligible patients. If appropriate and eligible, the clinician will contact patients to gauge interest in participating in the study. Patients will receive information by mail before the clinic visit where the intervention, the Serious Illness Conversation, will occur. The mailing will include a handout that prompts the patient to think about and pre-answer many of the questions the clinician may cover during the visit. Patients will consent and complete enrollment measures before the clinic visit. Patients may complete these measures via an electronic link or paper format. Follow-up links or paper versions of measures will be provided following the visit at the 24-48 hour mark, 1 month, and 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive the Serious Illness Care Program adapted for heart failure (SICP-HF). Clinicians are trained to integrate the communication intervention into routine outpatient heart failure care. Patients, care partners, and clinic staff participate in implementation and evaluation activities.
Behavioral: Serious Illness Care Program for Heart Failure (SICP-HF)
The Serious Illness Care Program adapted for heart failure is a behavioral communication intervention that includes clinician training and use of a structured Serious Illness Conversation Guide to facilitate values-based communication during the routine heart failure care. The intervention is implemented in an outpatient cardiology clinic and evaluated using a pre-post design.
The Survey of Illness Beliefs in Heart Failure
Survey of Illness Beliefs in Heart Failure: 14-item measure of the accuracy of patients' beliefs about heart failure. Items are rated on a 4-point Likert scale from 1 (strongly disagree) to 4 (strongly agree). Responses are scored to reflect accurate versus inaccurate illness beliefs, producing a total score ranging from 0 to 14. Higher scores indicate more accurate illness beliefs (better outcome).
Time frame: At enrollment, then at 1 month and 3 months post intervention
Anxiety
We will be using the State-Trait Anxiety Inventory (STAI), which is a 40-item self-report psychological test measuring two distinct types of anxiety: temporary, situation-based "state anxiety" and long-standing, baseline "trait anxiety". Administered to patient participants only. State anxiety (20 items) and trait anxiety (20 items) are subscales. Each subscale is scored from 20 to 80, with higher scores indicating greater anxiety (worse outcome).
Time frame: Trait anxiety will be measured at enrollment and at 1month and 3 months post-intervention. State anxiety will be measured 24-48 hours prior to intervention and again 24-48 hours post intervention.
Caregiver Preparedness
Preparedness for Caregiving Scale: 8-item measure assessing caregivers' perceived preparedness to provide care and manage caregiving-related tasks. Items are rated on a 5-point scale from 0 (not at all prepared) to 4 (very well prepared), with total scores ranging from 0 to 32. Higher scores indicate greater caregiver preparedness (better outcome).
Time frame: This survey will be administered at enrollment, then again at 1 month and 3 months post-intervention.
Kansas City Cardiomyopathy Questionnaire (KCQQ-12)
The KCCQ-12 is a survey for people with heart failure measuring physical limits, symptoms, quality of life, and social restrictions. 12-item patient-reported measure of health status in heart failure, including symptoms, physical limitations, social limitations, quality of life, and symptom stability. Scores are transformed to a 0-100 scale, with 0 representing the worst health status and 100 representing the best health status. Higher scores indicate better heart failure-related health status (better outcome).
Time frame: At enrollment and 1 month and 3 months post intervention.
Clinician-Patient Concordance in New York Heart Association Functional Class
Concordance between the clinician's assessment of the patient's current New York Heart Association (NYHA) functional class (Class I-IV) and the patient's heart failure health status as assessed using the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12). Clinician responses will be categorized as concordant, discordant, or intermediate based on prespecified mapping of KCCQ-12 responses to NYHA functional class. Lower discordance indicates better clinician-patient assessment agreement.
Time frame: Immediately following the clinician encounter
Quality of Communication
CollaboRATE: 3-item patient-reported measure of the quality of shared decision-making during a healthcare encounter. Each item is scored from 0 (no effort was made) to 9 (every effort was made). The total score ranges from 0 to 27, with higher scores indicating greater perceived shared decision-making (better outcome).
Time frame: One time 24-48 hours post-intervention.
Clinician-Patient Concordance in Quality of Life
Concordance between the clinician's assessment of the patient's current overall quality of life (excellent, very good, good, fair, or poor) and the patient's quality of life as assessed using the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12). Clinician responses will be categorized as concordant, discordant, or intermediate based on prespecified mapping of KCCQ-12 responses. Higher concordance indicates better clinician-patient assessment agreement.
Time frame: Immediately following the clinician encounter
Clinician-Patient Concordance in Heart Failure Symptom Frequency
Concordance between the clinician's assessment of the frequency of the patient's current heart failure symptoms (never, rarely, sometimes, often, or almost always) and the patient's symptom burden as assessed using the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12). Clinician responses will be categorized as concordant, discordant, or intermediate based on prespecified mapping of KCCQ-12 responses. Higher concordance indicates better clinician-patient assessment agreement.
Time frame: Immediately following the clinician encounter
Clinician-Patient Concordance in Expected Health Status Trajectory
Concordance between the clinician's anticipated patient health status trajectory over the next 6-12 months (significant improvement, some improvement, approximately the same, some decline, significant decline, or uncertain) and the patient's current health status as assessed using the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12). Clinician responses will be categorized as concordant, discordant, or intermediate based on prespecified mapping of KCCQ-12 responses. Higher concordance indicates better clinician-patient assessment agreement.
Time frame: Immediately following the clinician encounter
Clinician-Patient Concordance in Primary Factor Impacting Quality of Life
Concordance between the clinician's identification of the primary factor currently impacting the patient's quality of life (heart failure symptoms, other medical conditions/comorbidities, physical functioning or limitations, emotional/psychological concerns, social or family circumstances, financial or housing concerns, treatment burden/healthcare demands, other, or unable to assess) and the patient's reported health status and quality-of-life responses on the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12). Responses will be categorized as concordant, discordant, or intermediate according to prespecified mapping. Higher concordance indicates better clinician-patient assessment agreement.
Time frame: Immediately following the clinician encounter
Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.
Of 1,118 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 26 months is below that.
Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.